Terms: = Prostate cancer AND KMT2D, ENSG00000167548, 8085, MLL2
35 results:
1. CRISPR/Cas9 model of prostate cancer identifies Kmt2c deficiency as a metastatic driver by Odam/Cabs1 gene cluster expression.
Cai H; Zhang B; Ahrenfeldt J; Joseph JV; Riedel M; Gao Z; Thomsen SK; Christensen DS; Bak RO; Hager H; Vendelbo MH; Gao X; Birkbak N; Thomsen MK
Nat Commun; 2024 Mar; 15(1):2088. PubMed ID: 38453924
[TBL] [Abstract] [Full Text] [Related]
2. Epigenetic-focused CRISPR/Cas9 screen identifies (absent, small, or homeotic)2-like protein (ASH2L) as a regulator of glioblastoma cell survival.
Ozyerli-Goknar E; Kala EY; Aksu AC; Bulut I; Cingöz A; Nizamuddin S; Biniossek M; Seker-Polat F; Morova T; Aztekin C; Kung SHY; Syed H; Tuncbag N; Gönen M; Philpott M; Cribbs AP; Acilan C; Lack NA; Onder TT; Timmers HTM; Bagci-Onder T
Cell Commun Signal; 2023 Nov; 21(1):328. PubMed ID: 37974198
[TBL] [Abstract] [Full Text] [Related]
3. Genomic alterations related to HPV infection status in a cohort of Chinese prostate cancer patients.
Lang B; Cao C; Zhao X; Wang Y; Cao Y; Zhou X; Zhao T; Wang Y; Liu T; Liang W; Hu Z; Tian X; Zhang J; Yan Y
Eur J Med Res; 2023 Jul; 28(1):239. PubMed ID: 37461056
[TBL] [Abstract] [Full Text] [Related]
4. Histone methyltransferase kmt2d promotes prostate cancer progression through paracrine IL-6 signaling.
Zhang J; Ye Y; Xu Z; Luo M; Wu C; Zhang Y; Lv S; Wei Q
Biochem Biophys Res Commun; 2023 May; 655():35-43. PubMed ID: 36924677
[TBL] [Abstract] [Full Text] [Related]
5. Whole-exome sequencing analysis of NSCLC reveals the pathogenic missense variants from cancer-associated genes.
Kumar S U; Balasundaram A; Cathryn R H; Varghese RP; R S; R G; Younes S; Zayed H; Doss C GP
Comput Biol Med; 2022 Sep; 148():105701. PubMed ID: 35753820
[TBL] [Abstract] [Full Text] [Related]
6. Genomic landscape of microsatellite instability in Chinese tumors: A comparison of Chinese and TCGA cohorts.
Li Z; Jia Y; Zhu H; Yuan H; Xing X; Xin Y; Ma T; Pang F; Zhang Y; Hu Y; Jia S; Ji J
Int J Cancer; 2022 Oct; 151(8):1382-1393. PubMed ID: 35567574
[TBL] [Abstract] [Full Text] [Related]
7. Genome-wide CRISPR screen identifies PRC2 and kmt2d-COMPASS as regulators of distinct EMT trajectories that contribute differentially to metastasis.
Zhang Y; Donaher JL; Das S; Li X; Reinhardt F; Krall JA; Lambert AW; Thiru P; Keys HR; Khan M; Hofree M; Wilson MM; Yedier-Bayram O; Lack NA; Onder TT; Bagci-Onder T; Tyler M; Tirosh I; Regev A; Lees JA; Weinberg RA
Nat Cell Biol; 2022 Apr; 24(4):554-564. PubMed ID: 35411083
[TBL] [Abstract] [Full Text] [Related]
8. Detection of disease-causing mutations in prostate cancer by NGS sequencing.
Mangolini A; Rocca C; Bassi C; Ippolito C; Negrini M; Dell'Atti L; Lanza G; Gafà R; Bianchi N; Pinton P; Aguiari G
Cell Biol Int; 2022 Jul; 46(7):1047-1061. PubMed ID: 35347810
[TBL] [Abstract] [Full Text] [Related]
9. In-silico identification of frequently mutated genes and their co-enriched metabolic pathways associated with prostate cancer progression.
Singh AN; Sharma N
Andrologia; 2021 Dec; 53(11):e14236. PubMed ID: 34468989
[TBL] [Abstract] [Full Text] [Related]
10. Immune infiltration phenotypes of prostate adenocarcinoma and their clinical implications.
Ma Z; Cheng X; Yue T; Shangguan X; Xin Z; Zhang W; Pan J; Wang Q; Xue W
Cancer Med; 2021 Aug; 10(15):5358-5374. PubMed ID: 34128342
[TBL] [Abstract] [Full Text] [Related]
11. Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2-ERG fusions.
Chalmers ZR; Burns MC; Ebot EM; Frampton GM; Ross JS; Hussain MHA; Abdulkadir SA
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):558-566. PubMed ID: 33420417
[TBL] [Abstract] [Full Text] [Related]
12. Distinct Genomic Alterations in prostate Tumors Derived from African American Men.
Liu W; Zheng SL; Na R; Wei L; Sun J; Gallagher J; Wei J; Resurreccion WK; Ernst S; Sfanos KS; Isaacs WB; Xu J
Mol Cancer Res; 2020 Dec; 18(12):1815-1824. PubMed ID: 33115829
[TBL] [Abstract] [Full Text] [Related]
13. Small molecule inhibitors of the prostate cancer target kmt2d.
Yu Q; Liao Z; Liu D; Xie W; Liu Z; Liao G; Wang C
Biochem Biophys Res Commun; 2020 Dec; 533(3):540-547. PubMed ID: 32988590
[TBL] [Abstract] [Full Text] [Related]
14. Genomic Profiling of prostate cancers from Men with African and European Ancestry.
Koga Y; Song H; Chalmers ZR; Newberg J; Kim E; Carrot-Zhang J; Piou D; Polak P; Abdulkadir SA; Ziv E; Meyerson M; Frampton GM; Campbell JD; Huang FW
Clin Cancer Res; 2020 Sep; 26(17):4651-4660. PubMed ID: 32651179
[TBL] [Abstract] [Full Text] [Related]
15. Targeted next-generation sequencing for locally advanced prostate cancer in the Korean population.
Suh J; Jeong CW; Choi S; Ku JH; Kim HH; Kim KS; Kwak C
Investig Clin Urol; 2020 Mar; 61(2):127-135. PubMed ID: 32158963
[TBL] [Abstract] [Full Text] [Related]
16. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant prostate cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
[TBL] [Abstract] [Full Text] [Related]
17. Integrative Exome Sequencing Analysis in Castration-Resistant prostate cancer in Chinese Population.
Hao L; Li H; Zhang S; Yang Y; Xu Z; Zhang Y; Liu Z
Curr Pharm Biotechnol; 2020; 21(2):140-148. PubMed ID: 31580249
[TBL] [Abstract] [Full Text] [Related]
18. Loss of kmt2d induces prostate cancer ROS-mediated DNA damage by suppressing the enhancer activity and DNA binding of antioxidant transcription factor FOXO3.
Lv S; Wen H; Shan X; Li J; Wu Y; Yu X; Huang W; Wei Q
Epigenetics; 2019 Dec; 14(12):1194-1208. PubMed ID: 31232159
[TBL] [Abstract] [Full Text] [Related]
19. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S; Yim S; Park H
Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
[TBL] [Abstract] [Full Text] [Related]
20. Integrative molecular characterization of Chinese prostate cancer specimens.
Lv SD; Wang HY; Yu XP; Zhai QL; Wu YB; Wei Q; Huang WH
Asian J Androl; 2020; 22(2):162-168. PubMed ID: 31134918
[TBL] [Abstract] [Full Text] [Related]
[Next]
